Investors & Media

Whats new.

Press releases

Press releases.

Immutep Reports Supportive Efficacy Data from the Phase IIb AIPAC Study; Overall Survival Data Expected in Late 2020

March 25th 2020
press releases

Immutep’s Partner, EOC Pharma, Reports Completion of Recruitment of Phase I Study of Efti

March 20th 2020
press releases

Immutep Receives Second IND Approval for Efti from US FDA

March 9th 2020
press releases

Investor updates

Investor updates.

Investor Update - November 2019

November 22nd 2019
investor updates

Investor Update - January 2019

January 31st 2019
investor updates

Investor Update - June 2018

June 19th 2018
investor updates

Analyst reports

Analyst reports.

Bell Potter - Phase 2b AIPAC trial results provide path forward in metastatic breast cancer (Analyst: Tanushree Jain tnjain@bellpotter.com.au)

March 27th 2020
analyst reports

JonesTrading - AIPAC Setback Leaves a Mark on Efti’s Otherwise Impeccable Clinical Report Card, but Don’t Warrant a Failing Grade for Immutep

March 26th 2020
analyst reports

goetzpartners securities - Efti breast trial: Down certainly not out

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

March 26th 2020
analyst reports